Abstract. The present study aimed to investigate the effect of avicularin on rheumatoid arthritis (RA) in vitro, and additionally explore the molecular mechanism. To perform this investigation, an in vitro model of RA was established by treatment of the human RA synovial MH7A cell line with tumor necrosis factor-α (TNF-α). MH7A cells were then treated with various concentrations (10, 30, 100 and 300 µM) of avicularin. Then, the levels of inflammatory factors [interleukin (IL)-1β, IL-6, IL-8, matrix metalloproteinase (MMP)-1 and MMP-13] were measured by ELISA. Cell viability and apoptosis were detected using an MTT assay and flow cytometry, respectively. In addition, the expression levels of genes and proteins were determined reverse transcription quantitative polymerase chain reaction and western blot analysis. The results of the present study indicated that avicularin significantly decreased the levels of inflammatory factors (IL-1β, IL-6, IL-8, MMP-1 and MMP-13), previously increased by TNF-α, in a dose-dependent manner. Concurrently, avicularin inhibited the mRNA and protein expression levels of iNOS and COX-2 increased by TNF-α. It was also identified that TNF-α administration significantly promoted MH7A cell viability and inhibited cell apoptosis, and avicularin treatment dose-dependently inhibited MH7A cell viability and induced cell apoptosis. In addition, these data suggested that avicularin prevented the activation of the mitogen-activated protein kinase kinase (MEK)/nuclear factor kappa light-chain-enhancer of activated B-cells (NF-κB) pathway activated by TNF-α. Taken together, these results demonstrated that avicularin may inhibit the inflammatory response, prevent cell viability and induce apoptosis in human RA synovial cells through preventing the activation of the MEK/NF-κB pathway.
Introduction
Rheumatoid arthritis (RA) is a common chronic autoimmune inflammatory disease of unknown etiology that affects 1% of the global population (1) (2) (3) . In China, the prevalence of RA is 0.24-0.50%, and RA is more common among women compared with men (4) . The primary features of rheumatoid arthritis are joint swelling, joint stiffness and deformity, and cartilage destruction (5, 6) . At present, the pathogenesis of RA has not been fully elucidated, but it is generally accepted that RA is caused by the interaction of genetic, immune and environmental factors (7) . The current treatment of RA is primarily invasive anti-rheumatic therapy in the early stages of the disease. In order to avoid potential adverse reactions caused by second-line drugs, non-invasive and highly specific diagnostic and therapeutic methods are necessary.
Synovial fibroblasts (SFs), also known as fibroblast-like synoviocytes, have been demonstrated to serve an important role in the pathogenesis of RA, and their tumor-like proliferation leads to the development of synovial hyperplasia (8, 9) . During RA, activated SFs accumulate in the hyperplastic synovium of patients with RA. Increased levels of inflammatory cytokines, chemokines and matrix metalloproteinases (MMPs) mediate inf lammation and cartilage degradation, eventually leading to joint destruction (9) . At present, basic in vitro experiments using RA SFs have been performed to examine the pathogenesis of RA, in order to provide a theoretical basis for the exploration of RA ideal treatment methods (10) (11) (12) . At present, although great progress has been made in the therapeutic strategy of RA, the efficacy remains unsatisfactory. Therefore, novel treatment therapies for RA are urgently required.
Avicularin, quercetin-3-α-L-arabinofuranoside, is a bio-active flavonol that may be isolated from a number of plants. Flavonoids have been previously suggested to exhibit various biological properties, including hepatoprotective, anti-oxidative, anti-allergic, anti-tumor and anti-inflammatory activities (13) (14) (15) (16) (17) (18) . Quercetin (19, 20) and other flavonoids (21) have also been demonstrated to serve a role in RA. Avicularin is a glycoside of quercetin, and quercetin is lipophilic while avicularin is hydrophilic, and they may differ in absorption rates (22) . Although the biological activities of quercetin, an aglycone of avicularin, have been extensively examined, the biological properties of avicularin itself have not been fully studied. A recent study revealed that avicularin may reverse multidrug resistance in human gastric cancer by increasing the expression levels of B-cell lymphoma 2 (Bcl-2)-associated X protein (Bax) and BOK (16) . Vo et al (17) suggested that avicularin serves an anti-inflammatory role by inhibiting the extracellular signal-related kinase signaling pathway in lipopolysaccharide-stimulated RAW 264.7 macrophages. Fujimori and Shibano (18) indicated that avicularin may suppresses lipid accumulation in mouse adipocytic 3T3-L1 cells. These data indicated that avicularin has a specific regulatory effect in cell growth and the inflammatory response, suggesting that it may have a certain effect on RA development by regulating the growth and inflammatory response of RA SFs. However, to the best of our knowledge, no study has been conducted investigating the effects of avicularin in RA.
The aim of the present study was to investigate the effect and the underlying molecular mechanisms of avicularin in RA treatment in vitro. The in vitro model of RA was established by treatment of the human rheumatoid arthritis fibroblast-like synoviocytes MH7A cell line with tumor necrosis factor-α (TNF-α), a well-recognized cell model that is widely used in in vitro studies of RA (23) (24) (25) . The current study demonstrated that avicularin inhibited the inflammatory response and cell viability, and induced apoptosis in TNF-α-treated human RA synovial cells through preventing the activation of the mitogen-activated protein kinase kinase/nuclear factor kappa light-chain-enhancer of activated B-cells pathway.
Materials and methods
Cell culture. The human RA synovial MH7A cell line was obtained from Shanghai Guandao Biological Engineering Co., Ltd. (Shanghai, China; cat no. C0878). Cells were grown in RPMI-1640 medium (Hyclone; GE Healthcare Life Sciences, Logan, UT, USA) containing 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 1% penicillin-streptomycin solution (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), and incubated at 37˚C with 5% CO 2 .
Cell treatment. MH7A cells were pre-treated with various concentrations of avicularin (10, 30 , 100 and 300 µM) for 2 h, then the cells were subjected to treatment with TNF-α (10 ng/ml; Sigma-Aldrich; Merck KGaA) at room temperature for 24 h to establish the in vitro model of RA. Cells in the control group were treated with normal RPMI-1640 medium.
MTT assay. An MTT assay was used to detect cell viability. The MH7A cells were seeded into each well (5x10 5 cells per well) and incubated with various concentrations of avicularin (10, 30 , 100 and 300 µM) for 24 h at 37˚C. Then, 0.5 mg/ml MTT (in PBS) was added to every well, and the cells were incubated for an additional 3 h at 37˚C with 5% CO 2 . Dimethyl sulfoxide was used to dissolve the formazan crystals. Finally, absorbance was detected at 590 nm using a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
Cell apoptosis assay. MH7A cells were treated with 10, 30, 100 or 300 µM avicularin and 10 ng/ml TNF-α. Then, MH7A cell apoptosis was analyzed using an Annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit ELISA. To detect the production of interleukin (IL)-1β (cat. no. Ab100562), IL-6 (cat no. Ab46027), IL-8 (cat. no. Ab46032), MMP-1 (cat no. Ab100603) and MMP-13 (cat. no. Ab100605), the MH7A cell culture medium was collected by centrifugation at 4˚C and 1,048 x g for 10 min. ELISAs were performed according to the manufacturer's protocol of each ELISA kit (all Abcam, Cambridge, UK).
Reverse transcription quantitative polymerase chain reaction (RT-qPCR).
Total RNA from MH7A cells was isolated using TRIzol ® reagent (Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. cDNA was generated using the PrimeScript™ RT reagent kit (Takara Bio, Inc., Otsu, Japan) following the manufacturer's protocol. qPCR was performed by using the SYBR ® Premix Ex Taq™ II (Takara Bio Inc.). Amplification conditions were as following: 95˚C for 10 min, followed by 37 cycles at 95˚C for 15 sec and 72˚C for 30 sec and 78˚C for 1.5 min, following which samples were stored at 4˚C. GAPDH was used as an internal control. Primers are stated in Table I . Relative gene expression was analyzed by performing the 2 -ΔΔCq method (26) .
Western blot analysis. MH7A cells were treated with 10, 30, 100 or 300 µM avicularin and 10 ng/ml TNF-α. Then, total proteins from MH7A cells were isolated using radioimmunoprecipitation assay lysis buffer (Beijing Solarbio Science and Technology Co., Ltd., Beijing, China). Statistical analysis. Data are presented as the mean ± standard deviation. SPSS 16.0 statistical software (SPSS, Inc., Chicago, IL, USA) was used for all statistical analyses. The associations between two groups were analyzed by a paired Student's t-test, and the comparisons among more than two groups were performed using a one-way analysis of variance followed by a Student-Newman-Keuls post-hoc test. P<0.05 was considered to indicate a statistically significant difference. Avicularin inhibits the expression of iNOS and COX-2 increased by TNF-α. Then, the effect of avicularin treatment on iNOS and COX-2 expression was examined using RT-qPCR and western blot analysis. The results indicated that avicularin administration dose-dependently inhibited the protein ( Fig. 2A) and mRNA ( Fig. 2B and C) expression of iNOS and COX-2, which were increased by TNF-α treatment in MH7A cells (Fig. 2) .
Results

Avicularin inhibits the production of inflammatory factors
Avicularin inhibits the TNF-α-dependent increase in MH7A
cell viability. To examine whether avicularin affected the cell viability of MH7A cells, an MTT assay was performed. Table I . Primer sequences of reverse transcription quantitative polymerase chain reaction. It was identified that TNF-α treatment significantly increased the cell viability of MH7A cells, while avicularin dose-dependently prevented the cell viability of MH7A cells (Fig. 3) .
Primer (5'-3') -------------------------------------------------------------------------------------------------------------------------------------------------------------
Avicularin induces MH7A cell apoptosis inhibited by TNF-α.
To investigate the effect of avicularin on MH7A cell apoptosis, flow cytometry was performed. As indicated in Fig. 4A and B, compared with the control group, the number of apoptotic cells in the TNF-α treatment group was significantly decreased, and avicularin dose-dependently induced MH7A cell apoptosis. Concomitantly, the expression levels of apoptosis-associated proteins Bcl-2 and Bax were measured. The results suggested that TNF-α treatment significantly increased Bcl-2 expression and inhibited Bax expression in MH7A cells. Compared with the TNF-α-alone treatment group, the level of Bcl-2 was notably decreased and Bax was increased by avicularin treatment in a dose-dependent manner ( Fig. 4C-E) .
Avicularin prevents the activation of the MEK/nuclear factor kappa light-chain-enhancer of activated B-cells (NF-κB)
pathway activated by TNF-α. Finally, to explore the molecular mechanism of the effect of avicularin treatment on MH7A cells, the MEK/NF-κB pathway was analyzed. As hypothesized, it was identified that TNF-α significantly increased the protein levels of p-MEK/1/2 and p-p65, and avicularin treatment dose-dependently decreased the protein expression levels of p-MEK/1/2 and p-p65 (Fig. 5) .
Discussion
In the present study, it was demonstrated that avicularin inhibited the production of inflammatory factors enhanced by TNF-α treatment. The results also indicated that TNF-α administration significantly promoted MH7A cell viability and inhibited cell apoptosis, and avicularin treatment dose-dependently inhibited MH7A cell viability and induced cell apoptosis through repressing the MEK/NF-κB pathway. It was revealed that avicularin may be a promising therapeutic agent for the treatment of RA. RA is a systemic autoimmune disease characterized by chronic inflammation, synovial hyperplasia, and bone and cartilage destruction as the primary pathological symptoms (27, 28) . At present, there is no drug that may completely controls the condition of RA, and prevents bone destruction and erosion; a method of specifically and successfully treating RA has not yet been identified. The treatment and successful cure of RA remains a challenge to the global medical community, and requires additional study.
Avicularin, a bioactive flavonol isolated from a large number of plants, has been identified to exhibit a variety of pharmacological properties, including anti-inflammatory effects (16, 17) . Avicularin serves an important role in regulating the inflammatory response and cell growth. Avicularin is a glycoside of quercetin, and quercetin has been suggested to serve a protective role in RA (19, 20) ; however, the effect of avicularin on RA remains unknown. A large number of studies have indicated that SFs are the primary cells of synovial hyperplasia and that they serve a key role in the pathogenesis of RA synovium (9) (10) (11) (12) . SFs participate in the entire process of inflammation and angiogenesis, eventually causing invasive destruction of bone joints (29, 30) . At present, to the best of our knowledge, the specific effect and mechanism of avicularin on SFs in RA remains unclear. Therefore, the present study was conducted to explore whether avicularin exerted an effect on RA through regulating SFs.
Firstly, an in vitro model of RA was established by treating the human RA synovial MH7A cell line with 10 ng/ml TNF-α for 24 h. It was identified that TNF-α treatment significantly increased the inflammatory response in Figure 5 . Effect of avicularin on MEK/nuclear factor kappa light-chain-enhancer of activated B-cells pathway in MH7A cells. MH7A cells were pre-treated with various concentrations of avicularin (10, 30, 100 and 300 µM) for 2 h, then the cells were subjected to treatment with 10 ng/ml TNF-α at room temperature for 24 h. The protein level of p-MEK1/2 and p-p65 was measured using (A) western blot analysis, and the data for (B) p-MEK1/2 and (C) p-p65 were analyzed. Data are expressed as the mean ± standard deviation. MH7A cells, evidenced by increased expression levels of inflammatory factors including IL-1β, IL-6, IL-8, MMP-1 and MMP-13. It was also identified that TNF-α treatment significantly promoted cell viability and inhibited cell apoptosis in MH7A cells. As hypothesized, additional analysis indicated that avicularin administration dose-dependently decreased the levels of IL-1β, IL-6, IL-8, MMP-1 and MMP-13, inhibited MH7A cell viability and induced cell apoptosis.
iNOS is a major producer of NO and serves an important role in the progression of inflammatory diseases, including RA (31). COX-2, which is involved in the inflammatory response and is increased in inflammation-associated cells following cytokine stimulation during the immune reaction, was revealed to be upregulated during RA development (31, 32) . Consistent with previous studies (31, 33) , the present study identified that TNF-α treatment significantly increased the expression levels of iNOS and COX-2 in MH7A cells, and the increased levels of iNOS and COX-2 caused by TNF-α treatment were dose-dependently decreased by avicularin administration. To additionally explore the underlying mechanism of the effect of avicularin on MH7A cells, the MEK-NF-κB pathway, which has been identified to be repressed by avicularin in RAW 264.7 macrophages (17), was investigated. The results suggested that the activation of MEK-NF-κB pathway caused by TNF-α treatment was prevented by avicularin treatment in a dose-dependent manner.
In summary, to the best of our knowledge, the present study identified for the first time that avicularin inhibited the inflammatory response, prevented cell viability and induced apoptosis in TNF-α-treated human RA synovial cells through preventing the activation of the MEK/NF-κB pathway. Therefore, avicularin may serve as a promising therapeutic agent for the treatment of RA. However, this is a preliminary study examining the effect of avicularin on RA; the protective effect of avicularin on RA requires additional study. Compared with other flavonoids, the advantage of using avicularin for RA is largely unclear; future studies are required to compare the effects of avicularin and other flavonoids on RA. In addition, the in vitro model of RA is significantly different from in vivo RA in humans; therefore, additional in vivo experiments and clinical studies are also required to demonstrate the protective effect of avicularin on RA. Future studies conducted by this group will examine these issues in-depth.
